Hologic Inc
(BSP:H1OL34)
R$
447.04
0 (0%)
Market Cap: 101.45 Bil
Enterprise Value: 103.43 Bil
PE Ratio: 22.62
PB Ratio: 3.40
GF Score: 86/100 Hologic Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019 / 06:35PM GMT
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst
Okay, thank you, and good afternoon, everybody. I'm Jack Meehan, the life science, tools and diagnostics analyst here at Barclays and really pleased to be joined by Hologic team: CFO, Karleen Oberton; as well as Head of Investor Relations, Mike Watts.
Before kicking it off, we're going to start with 3 audience response questions, so please use the BlackBerrys.
Question #1, what do you view as Hologic's organic growth profile over the next 3 years?
(Voting)
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst
And you'll give us the answer later.
Michael J. Watts
Hologic, Inc. - VP of IR & Corporate Communications
Or not.
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst
Or not. Low to mid-single digits. Okay. Next question. Do you expect organic growth to accelerate from here and when?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot